CPD Events

Defining new expectations for overall survival with nivolumab and ipilimumab for the first-line treatment of intermediate/poor-risk advanced RCC: Insights from ASCO GU 2024

07 Apr 2024

About the event

The aim of the webinar is to enhance the target audience’s understanding of using OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab) for the treatment of first-line advanced renal cell carcinoma (1L aRCC) and explore the 1L treatment selection process for choosing either I-O/TKI or I-O/I-O combinations in eligible patients.

CPD Provider

Inspired Science

Send an enquiry

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inspired Science

Inspired Science

Tell the science. Inspire the people. Inspired Science, an innovative communications company based in London.

Want to learn more?